Zenas BioPharma, Inc. (ZBIO) AI Stock Analysis

• Market Cap: $432.15M
• Dividend Yield: N/A
• Average Volume (3M): 172.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -3.90
• Shares Outstanding: 41,834,183
• 10 Day Avg. Volume: 266,728
• 30 Day Avg. Volume: 172,076
• PEG Ratio: 0.00
• Price to Book (P/B): -3.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.15
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: 9.33
• Enterprise Value/Gross Profit: 43.52
• Enterprise Value/Ebitda: -1.25
• 1Y Price Target: $36.25
• Price Target Upside: 250.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 55 Neutral
• Price Target: $11.50 ▲(11.33%Upside)

Zenas BioPharma's overall stock score is driven by its challenging financial performance and valuation concerns, which are partially offset by strong technicals and positive corporate developments. The company's ability to improve financial stability and capitalize on clinical advancements will be crucial.

Positive Factors

Clinical Validation

There are no approved therapies for IgG4-RD, and Amgen announced positive Phase 3 MITIGATE trial results for CD19 therapy Uplinza, which helps validate obexelimab’s mechanism for utilizing CD19 binding.

Market Expansion

Zenas entered into a license agreement with Bristol-Myers Squibb granting an exclusive license to obexelimab in the Asian BMS territory, supporting the developmental merits of Zenas’ autoimmune platform.

Therapeutic Advancements

Obexelimab is designed for a self-administered subcutaneous injection regimen potentially offering convenience and safety differentiation.

Negative Factors

Clinical Trial Timeline

Topline results from the pivotal Phase 3 INDIGO trial in IgG4-related disease are anticipated around year-end 2025.

Market Perception

The company will continue to work on building story/value, particularly around differentiated inhibition (vs. depletion) MOA, potentially driving clinical benefit and eventual commercial utility.

Stock Performance

Stock performance has been underwhelming since IPO, which is a disconnect from the fundamental value.

Zenas BioPharma, Inc. Business Overview & Revenue Model

Company Description

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

How the Company Makes Money

Zenas BioPharma, Inc. generates revenue primarily through the development and commercialization of its proprietary pharmaceutical products. The company earns money by selling its approved drugs directly to healthcare providers, hospitals, and distributors. Additionally, Zenas engages in strategic partnerships and licensing agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on product sales. These collaborations often enhance the company's market reach and provide additional funding for research and development activities. Furthermore, Zenas may receive government grants or subsidies aimed at promoting innovation in the biotech sector.

Zenas BioPharma, Inc. Financial Statement Overview

Summary

Zenas BioPharma is experiencing substantial revenue decline and persistent losses, with a strong equity recovery providing some balance sheet stability. However, significant cash flow challenges driven by operational cash burn underscore the need for improvements.

Income Statement

Zenas BioPharma has shown a significant decline in revenue from $50 million in 2023 to $5 million in 2024, indicating a severe contraction. The gross profit margin remains high due to zero cost of goods sold, yet the company faces substantial operating losses with negative EBIT and net income, highlighting ongoing profitability challenges.

Balance Sheet

The company has a strong equity position with a debt-to-equity ratio of only 0.003, suggesting low financial leverage. However, the negative equity in previous years indicates past difficulties, although recent improvements in stockholder's equity to $312 million show significant recovery. The equity ratio of approximately 84% is a positive indicator of financial stability.

Cash Flow

Zenas BioPharma's free cash flow remains negative, with a decline in operating cash flow from -$30 million to -$120 million. While financing activities have injected significant cash, the operational cash burn is a concern. The operating cash flow to net income ratio is negative, reflecting inefficiency in converting income into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
15.00M	5.00M	50.00M	0.00
	Gross Profit
15.00M	5.00M	50.00M	0.00
	EBIT
-183.64M	-163.89M	-37.15M	-76.20M
	EBITDA
-169.96M	-163.75M	-27.03M	-75.12M
	Net Income Common Stockholders
-162.76M	-156.99M	-37.12M	-119.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
312.38M	350.77M	56.86M	67.21M
	Total Assets
333.77M	369.97M	68.18M	74.58M
	Total Debt
1.23M	1.00M	21.11M	1.53M
	Net Debt
-195.33M	-318.74M	-35.74M	-65.68M
	Total Liabilities
49.45M	57.51M	293.90M	266.87M
	Stockholders Equity
284.32M	312.46M	-225.72M	-192.29M
Cash Flow		Free Cash Flow
-137.75M	-119.81M	-30.55M	-67.85M
	Operating Cash Flow
-137.62M	-119.67M	-30.53M	-65.65M
	Investing Cash Flow
-116.80M	-30.55M	-17.00K	-2.20M
	Financing Cash Flow
413.67M	412.96M	20.12M	59.39M

Zenas BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMLX	57 Neutral	$492.06M	―	-83.24%	―	-100.32%	-197.69%
ETON	56 Neutral	$383.49M	―	-22.95%	―	40.88%	-579.73%
ZBIO	55 Neutral	$432.15M	―	-115.47%	―	―	―
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
CKPT	45 Neutral	$370.71M	―	-1869.55%	―	-60.19%	56.60%
TRML	45 Neutral	$505.55M	―	-26.14%	―	―	74.59%
RAPP	44 Neutral	$408.41M	―	-33.14%	―	―	―

Zenas BioPharma, Inc. Corporate Events

Zenas BioPharma Announces Board Changes at Annual Meeting

On June 10, 2025, Zenas BioPharma, Inc. held its 2025 Annual Meeting of Stockholders. During this meeting, Ting (Tim) Xiao resigned from the Board of Directors, reducing the board size from nine to eight. Stockholders elected Leon O. Moulder, Jr. and Hongbo Lu, Ph.D. as Class I directors for a three-year term and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ZBIO) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.

Zenas BioPharma to Present at Jefferies Conference

Zenas BioPharma announced its participation in the Jefferies Global Healthcare Conference in June 2025, where it will present its investor presentation. The company is advancing its clinical trials for Obexelimab, a potentially highly differentiated therapy for autoimmune diseases, with significant upcoming data readouts expected in late 2025 and mid-2026. These developments could position Zenas BioPharma as a competitive player in the biotechnology market, potentially impacting stakeholders positively.

The most recent analyst rating on (ZBIO) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.